Halozyme Therapeutics Inc. and GSK have entered into a global collaboration and license agreement. Under the terms, GSK has licensed Halozyme’s ENHANZE drug delivery technology to develop and potentially commercialize subcutaneous formulations for multiple oncology targets, specifically including antibody-drug conjugates (ADCs).
A breakthrough for the ADC therapeutic class This agreement marks a significant milestone as the first ENHANZE collaboration to include ADC targets:
-
Reducing treatment burden: Moving from intravenous infusion to subcutaneous injection significantly reduces the treatment burden for cancer patients, providing easier access to care.
-
Optimizing benefit-risk profile: Halozyme believes that subcutaneous delivery of ADCs via ENHANZE may meaningfully improve the safety and efficacy of these treatments, positioning the company at the forefront of a rapidly growing therapeutic class.
Deal structure and commercial value
-
Payment terms: GSK will make an upfront payment to Halozyme, followed by potential future milestone payments related to development and commercialization success.
-
Royalties: Halozyme is entitled to receive royalties on net sales of any products incorporating the ENHANZE technology.
-
Expansion option: The deal includes an option for GSK to add additional drug targets in the future.
GSK leadership highlighted that novel approaches are essential to ease the burden on cancer patients. By combining GSK’s promising oncology targets with Halozyme’s “gold standard” delivery technology, the partnership looks forward to progressing its first clinical programs rapidly.